GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » 12-1 Month Momentum %

abrdn Life Sciences Investors (abrdn Life Sciences Investors) 12-1 Month Momentum % : -1.53% (As of Apr. 29, 2024)


View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-29), abrdn Life Sciences Investors's 12-1 Month Momentum % is -1.53%.

The industry rank for abrdn Life Sciences Investors's 12-1 Month Momentum % or its related term are showing as below:

HQL's 12-1 Month Momentum % is ranked worse than
58.25% of 1746 companies
in the Asset Management industry
Industry Median: 1.915 vs HQL: -1.53

Competitive Comparison of abrdn Life Sciences Investors's 12-1 Month Momentum %

For the Asset Management subindustry, abrdn Life Sciences Investors's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


abrdn Life Sciences Investors's 12-1 Month Momentum % Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's 12-1 Month Momentum % falls into.



abrdn Life Sciences Investors  (NYSE:HQL) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


abrdn Life Sciences Investors  (NYSE:HQL) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


abrdn Life Sciences Investors 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Traded in Other Exchanges
N/A
Address
1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Executives
Todd Reit director C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher director 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino director C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor other: Director of Adviser C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc. other: Adviser 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar officer: VP and Chief Legal Officer 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols other: Director of Adviser 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard officer: President ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy officer: Secretary and Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari officer: Treasurer and CFO 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson officer: Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina officer: Chief Compliance Officer & VP 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Headlines

From GuruFocus

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 06-30-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire 06-30-2023

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 03-31-2022

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 02-15-2023

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 09-30-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-31-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-31-2020

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 06-30-2022